Disease of the airways in chronic obstructive pulmonary disease
- PMID: 12392034
- DOI: 10.1183/09031936.01.00234601
Disease of the airways in chronic obstructive pulmonary disease
Abstract
The pathological hallmarks of chronic obstructive pulmonary disease (COPD) are inflammation of the small airways (bronchiolitis) and destruction of lung parenchyma (emphysema). The functional consequence of these abnormalities is airflow limitation. Airway abnormalities and emphysema interact in a complex fashion in the development of airflow limitation in COPD. In an attempt to improve understanding of the role of the airways in COPD, the morphological counterparts of airflow limitation, the cellular inflammatory infiltrate in the airways and the relationship between emphysema type and airway abnormalities are reviewed. Significant correlation between airway remodelling and functional measurements are found in earlier stages of COPD. In advanced COPD, airflow limitation is reflected by airway narrowing, airway deformity and extent of emphysema. The cellular inflammatory infiltrate is mainly composed of neutrophils in early stages of COPD. However, the presence of CD8+ T-cells seems to differentiate smokers with COPD from smokers that would not develop the disease. The inflammatory changes and remodelling found in the airways and their contribution to airflow obstruction might be modulated by the type of emphysema smokers develop, with centrilobular emphysema showing more severe inflammatory changes and narrower airways than panlobular emphysema. In conclusion, the degree of airway involvement in chronic obstructive pulmonary disease can vary greatly for the same degree of airflow obstruction, depending on the type of emphysema smokers develop. If the underlying lung abnormalities in chronic obstructive pulmonary disease vary, as the evidence suggests, the study of cigarette-induced lung disease as a single entity will further delay understanding of chronic obstructive pulmonary disease.
Similar articles
-
Morphological and cellular basis for airflow limitation in smokers.Eur Respir J. 1994 Aug;7(8):1505-15. doi: 10.1183/09031936.94.07081505. Eur Respir J. 1994. PMID: 7957838 Review.
-
Pathophysiology of the small airways in chronic obstructive pulmonary disease.Respiration. 2012;84(2):89-97. doi: 10.1159/000341382. Epub 2012 Aug 6. Respiration. 2012. PMID: 22868355 Review.
-
Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema.Am J Respir Crit Care Med. 2002 Jul 1;166(1):105-10. doi: 10.1164/rccm.2111084. Am J Respir Crit Care Med. 2002. PMID: 12091179
-
Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2012 Aug 1;186(3):233-9. doi: 10.1164/rccm.201112-2142OC. Epub 2012 Jun 7. Am J Respir Crit Care Med. 2012. PMID: 22679009
-
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.Lancet. 2004 Aug 21-27;364(9435):709-21. doi: 10.1016/S0140-6736(04)16900-6. Lancet. 2004. PMID: 15325838 Review.
Cited by
-
Longitudinal decline in lung function: a community-based cohort study in Korea.Sci Rep. 2019 Sep 20;9(1):13614. doi: 10.1038/s41598-019-49598-9. Sci Rep. 2019. PMID: 31541126 Free PMC article.
-
Plasma Extracellular Vesicle miRNA Profiles Distinguish Chronic Obstructive Pulmonary Disease Exacerbations and Disease Severity.Int J Chron Obstruct Pulmon Dis. 2022 Nov 4;17:2821-2833. doi: 10.2147/COPD.S379774. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36381992 Free PMC article.
-
Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: Number 1 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.Eur Respir Rev. 2017 Jun 28;26(144):170003. doi: 10.1183/16000617.0003-2017. Print 2017 Jun 30. Eur Respir Rev. 2017. PMID: 28659502 Free PMC article. Review.
-
Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS).Respir Res. 2019 Jul 15;20(1):153. doi: 10.1186/s12931-019-1121-z. Respir Res. 2019. PMID: 31307479 Free PMC article.
-
Heart rate variability and its correlation with pulmonary function test of smokers.Heart Views. 2013 Jan;14(1):22-5. doi: 10.4103/1995-705X.107116. Heart Views. 2013. PMID: 23580921 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials